title: "First experience with JenaValve™: a single-centre cohort".
abstract: OBJECTIVE
  Since the introduction of transcatheter aortic valve implantation (TAVI), newer generation and novel devices such as the retrievable JenaValve™ have been developed. We evaluated the procedural and 6-month results of our first experience with implantation of the JenaValve™.
  
  
  RESULTS
  From June 2012 to December 2013, 24 consecutive patients (mean age 80 ± 7 years, 42 % male) underwent an elective transapical TAVI with the JenaValve™. Device success was 88 %. The mortality rate was 4 % at 30 days and 31 % at 6 months. TAVI reduced the mean transvalvular gradient (44.2 ± 11.1 mmHg vs. 12.3 ± 4.3 mmHg, p < 0.001) and increased the mean aortic valve area (0.8 3 ± 0.23 to 1.70 ± 0.44 cm(2)). A mild paravalvular leakage (PVL) occurred in 4 patients (18 %) and a moderate PVL in 1 patient (4 %). Mean New York Heart Association Functional Class improved from 2.9 ± 0.5 to 2.0 ± 0.8 at 30 days.
  
  
  CONCLUSIONS
  TAVI using the JenaValve™ prosthesis seems adequate and safe in this first experience cohort.
authors.affiliation: Department of Cardiology, St. Antonius Hospital Koekoekslaan 1, 3435, Nieuwegein, the Netherlands, v.nijenhuis@antoniusziekenhuis.nl.
authors.forename: V J
authors.initials: VJ
authors.lastname: Nijenhuis
authors.forename: M J
authors.initials: MJ
authors.lastname: Swaans
authors.forename: V
authors.initials: V
authors.lastname: Michiels
authors.forename: T
authors.initials: T
authors.lastname: de Kroon
authors.forename: R H
authors.initials: RH
authors.lastname: Heijmen
authors.forename: J M
authors.initials: JM
authors.lastname: Ten Berg